Headlands Technologies LLC Purchases 1,677 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Headlands Technologies LLC grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 54.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,764 shares of the life sciences company’s stock after buying an additional 1,677 shares during the quarter. Headlands Technologies LLC’s holdings in Integra LifeSciences were worth $169,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Cardinal Capital Management grew its holdings in Integra LifeSciences by 1.6% during the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after purchasing an additional 347 shares during the period. Hexagon Capital Partners LLC grew its stake in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the period. State of Michigan Retirement System raised its stake in Integra LifeSciences by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock valued at $592,000 after acquiring an additional 400 shares during the period. Signaturefd LLC lifted its holdings in Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Integra LifeSciences by 2.6% during the first quarter. Louisiana State Employees Retirement System now owns 19,600 shares of the life sciences company’s stock worth $695,000 after purchasing an additional 500 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART traded up $1.82 during mid-day trading on Tuesday, reaching $31.66. 570,989 shares of the company were exchanged, compared to its average volume of 1,093,591. Integra LifeSciences Holdings Co. has a 52 week low of $22.36 and a 52 week high of $46.75. The company’s 50 day moving average price is $28.79 and its 200 day moving average price is $34.49. The stock has a market capitalization of $2.49 billion, a PE ratio of 61.00, a PEG ratio of 1.08 and a beta of 1.11. The company has a quick ratio of 3.35, a current ratio of 4.68 and a debt-to-equity ratio of 1.15.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.55. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company’s revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.74 earnings per share. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.03 earnings per share for the current fiscal year.

Insider Buying and Selling at Integra LifeSciences

In other Integra LifeSciences news, Chairman Stuart Essig acquired 52,641 shares of the stock in a transaction dated Thursday, May 23rd. The stock was purchased at an average cost of $28.49 per share, for a total transaction of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on IART shares. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Oppenheimer cut Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 7th. JMP Securities cut their price objective on shares of Integra LifeSciences from $49.00 to $40.00 and set a “market outperform” rating for the company in a research report on Tuesday, May 7th. Truist Financial upped their target price on shares of Integra LifeSciences from $25.00 to $32.00 and gave the stock a “hold” rating in a report on Tuesday. Finally, Morgan Stanley boosted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $32.86.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.